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Abstract
Background: Vogt-Koyanagi-Harada (VKH) disease is a systemic autoimmune 
granulomatous disease that targets melanocyte-rich tissue with potentially visually-
threatening outcome for patients. It is manifested in eyes, inner ears, skin, and hair. 
Aim: This review aims to give a brief information about VKH disease, especially 
regarding the diagnosis and treatment. Conclusion: VKH disease is a diagnosis of 
exclusion, a comprehensive history taking and physical examinations are required 
for prompt treatment using immunosuppressive agent to improve patient outcomes. 
Clinical Significance: It is possible to treat this condition by applying diagnostic criteria. 
This requires a very thorough review of possible differential diagnosis and should then be 
treated with high corticosteroid immunosuppressive drugs. This is solely responsible for 
stopping the visual impairment and recurrence of the disease.
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Introduction
Vogt-Koyanagi-Harada (VKH) disease, known also as 
uveomeningoencephalitis syndrome, is a systemic autoimmune 
granulomatous disease affecting melanocyte-rich tissue, 
including eyes, inner ears, skin, and hair.[1] It is mediated by 
autoimmune activity affecting the tyrosinase (TYR) family 
and gp100.[2] Ocular-related conditions related to this disease 
including choroidal thickening, multifocal serous retinal 
detachment, and optic disk hyperemia.[3] The term VKH disease 
was given by Bruno and McPherson to encompass the previous 
reported uveomeningeal syndromes as one broad-spectrum 
entity.[4] The name of the disease is eponymous for honoring the 
findings of Alfred Vogt (1906) in Switzerland as the first person 
to describe the disease, Einosuke Harada (1926) in Japan for 
reporting five case series of primary posterior uveitis correlated 
with exudative retinal detachment and cerebrospinal fluid 
pleocytosis, and Yoshizo Koyanagi (1929) in Japan for reporting 
six case series and reviewing the earlier findings of the disease.[5]
The prevalence of VKH disease varied across the world. 
Higher cases were described in Asian, Hispanic, Indian, Native 
American, and Mediterrania, accounted for 7–22.4% of cases of 
uveitis.[6,7] VKH disease is also common in Japan, with 6.8–9.2% 
of all cases of uveitis.[6,7] Epidemiological data showed that VKH 
disease is more commonly found in young women between the 
ages of 20 and 50 years with a ratio of 2:1 to male.[8] However, 
cases of VKH disease have also been identified in children, the 
elderly or even with an equivalent gender distribution.[2] This 
condition had unknown causes, but thought to be associated to 
the genetic susceptibility, mainly related to Human Leukocyte 
Antigen (HLA) DRB1×0405.[9] Genetic susceptibility is 
responsible for initiating auto-inflammatory stage after viral 
infection, mainly mediated by T lymphocyte which is targetting 
tyrosinase-related proteins (TRP).[3,10-12]
Diagnosis of VKH disease primarily focused on the exclusion 
of any other eye disease and sufficient history, including ocular 
penetrating injury or intraocular surgery, infection, and systemic 
rheumatic diseases.[13,14] Many treatment strategies have been 
developed to cure VKH disease, including systemic corticosteroid 
(regional, oral, or intravenous), anti-metabolic, and alkylating 
agent.[9] Inadequate immunosuppressive treatment could lead 
into the chronic condition, potentially disrupting the visual 
ability with its complication, such as cataract and secondary 
glaucoma.[15]
Etiology
The exact cause of VKH disease is still unknown, mostly related 
to the genetic factor, but the actual inheritance pattern is still 
under investigation.[3] Some genes expression thought to be 
Umar and Siburian Vogt-koyanagi-harada disease as diagnosis of exclusion
2
associated with this condition, include HLA DRB1×0405 gene 
expression.[9] Evidence of HLA involvement as the key risk 
factor for this disease has been found in Brazil, Korea, Vietnam, 
Saudi Arabia, Japan, and Europe (especially Italy).[9,16] The gene 
expression causes autoimmune activation against melanocyte-
associated antigens after viral infection, such as Epstein-Barr 
virus and cytomegalovirus.[17,18]
Hypothetical evidence has shown that this disorder is linked 
to autoimmune reactions mediated by T-Helper 2 cells against 
TYR-like proteins in melanocyte, melanin, or retinal epithelial 
pigment, triggering inflammatory cascades involving cytokine, 
interleukin (IL)-17, IL-23, and IL-35.[10,11] The manifestation 
of VKH disease is related to the target tissue (melanocyte-
rich), causing ocular (uveitis), neurological (meningitis), 
(auditory) dysacousia, or even dermatological manifestation 
(vitiligo).[19,20]
Pathogenesis
The exact molecular mechanism of VKH disease is 
unknown, but the condition is believed to be associated with 
autoimmune mechanisms or infections. Recent concepts 
include the destruction of melanocyte-related antigens 
mediated by autoimmune T cell reactions.[3] These include 
TRP1 and 2 (TRP2) TYR, Pmel17/gp100, and MART-1/
Melan A.[3] Stimulated T lymphocytes are responsible to 
express the transmembrane protein CD 25, which is the 
alpha chain of the IL-2 receptor. Meanwhile, other cells 
express CD26 related to the deployment of the next T 
cell function.[21,22] This disease process is closely linked to 
several HLAs such as HLA-DR4, DR1, DRB1×0405, and 
DRB1×0410.[22]
Diffuse, non-necrotic granulomatous inflammation of the 
uvea is typical of VKH disease. Histopathological changes 
vary depending on the stage of the disease, ranging from 
granulomatous inflammation throughout the uvea, diffuse 
infiltration of lymphocytes and macrophages, the presence 
of epitheloid cells and giant cells showing ingested pigment 
granules, and serous retinal detachment.[22] When the process is 
chronic, there is a decrease in choroid melanocytes (sunset glow 
fundus), loss of epithelial retinal pigment cells, and development 
of chorioretinal adhesions. The mechanism leading to chronic 
recurrence will cause hyperplasia and metaplasia of the retinal 
pigment epithelium.[22]
Diagnosis
Diagnosis criteria for VKH were first published by the American 
Uveitis Society in 1978. This has two main components:[23]
1. No history of ocular trauma or surgery, and
2. Three of four potential findings of diagnosis (chronic bilateral 
iridocyclitis, posterior uveitis, neurological symptoms, and 
skin manifestations).[23]
The parameters were then amended by the International 
Nomenclature Committee in 2001. Its criteria include five 
components: 
1. No history of penetrating injuries or eye surgery
2. No evidence of any other eye condition
3. Bilateral eye involvement
4. Neurological dysfunction, and
5. Skin disorder.
After applying these criteria, the patient is then graded as 
taking complete disease (fulfilling all criteria), incomplete 
disease (following 1–3 results but only one out of 4 or 5), and 
probable disease (only meeting criteria 1–3).[1]
For a physician, while there are specific guidelines for the 
diagnosis of VKH disease, there are still drawbacks to be found, 
such as potentially temporary signs and symptoms, minimal or 
undetectable ocular and skin manifestations, as well as a variety 
of ocular manifestations of the disease by racial, geographical, 
and ethnic differences.[24]
After VKH disease was diagnosed, physician needs to classify 
it according to the disease stages which will shows very broad 
disease manifestations. It includes the prodromal phase (viral-
like symptoms, neurological [meningitis, cranial nerve paralysis, 
and focal lesion], auditory manifestation), acute uveitis phase 
(blurred vision, vitritis, papillitis, hyperemia, disc edema, and 
exudative retinal detachment), convalescent phase (alopecia, 
vitiligo, poliosis, and depigmented fundus sunset glow), and 
perilimbal vitiligo (Sugiura sign), as well as chronic recurrent 
phase (accompanied with complication including glaucoma, 
cataract, choroidal neovascularization, and fibrosis of the retina 
or choroid).[1,25]
The imaging modality is also essential for VKH disease 
identification. Some types include fundus fluorescein 
angiography, which is critical not only for the diagnosis but 
also for the follow-up and prognosis assessment,[2] indocyanine 
green angiography (ICG),[2,26] an invasive procedure responsive 
to the visualization of choroidal circulation,[2,24] B-scan 
ultrasonography, fundus autofluorescence for illustrating 
retinal epithelial pigment and outer layer of retina,[2] as well 
as optical coherence tomography (OCT) for determining 
choroidal thickness, measuring disease activity, and therapeutic 
response.[2] Full-field electroretinography (ERG) or multifocal 
ERG for the assessment of the electrophysiological function of 
the retina and microperimetry for the determination of light 
intensity in various parts of the retina (in conjunction with 
OCT) are other diagnostic modalities.[2] Specific causes of eye 
inflammation, such as erythrocyte sedimentation rate, C-reactive 
protein, antinuclear antibody, p-/c-antineutrophil cytoplasmic 
antibodies, and lumbar puncture for undetermined VKH disease 
(pleocytosis), may be established.[27]
Differential Diagnosis
Whenever a patient has neurological, ocular, 
otorhinolaryngological, and cutaneous manifestation, VKH 
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disease should always be considered. The differential diagnosis 
of sympathetic ophthalmia, central serous chorioretinopathy, 
epitheliopathy, and any retinal detachment that is secondary to 
systemic hypertension should be excluded from the investigation. 
Systemic lupus erythematosus, Wegener granulomatosis, 
amyloidosis, or sarcoidosis can be associated with the 
observations of immune-mediated sensorineural hearing loss.[24] 
In addition, malignancy (intraocular lymphoma, diffuse bilateral 
melanocytic uveal hyperplasia, and systemic lymphoma/
leukemia), inflammation (bilateral posterior scleritis, Multiple 
evanescent white dot syndrome) or infection (bacteria, fungus, 
tuberculosis, and syphilis) may also be identified as a differential 
diagnosis.[4,9]
Management
Two main processes of VKH disease therapy should include 
the treatment of the early uveitic/exudative acute stage and 
the maintenance of adequate therapy, including first-line non-
steroidal immunosuppressive medications, long enough to 
contribute to choroidal inflammation resolution, in addition to 
ICGA-assisted therapy tapering wherever possible.[28] Several 
treatment strategies have been implemented for the patient with 
VKH disease, including intravenous (methylprednisolone), oral 
(prednisone, methylprednisolone), or regional corticosteroid, 
antimetabolites, azathioprine, cyclosporine, as well as alkylating 
agents.[9,12]
VKH disease treatment primarily linked to systemic 
corticosteroid therapy. There are some principles for the 
implementation of this procedure: Early initial treatment in 
accordance with intense treatment (high dose of prednisolone/
prednisone, 1 mg/kgBW daily, with a maximum dose of 
80 mg/day) and long-term therapy (at least 6 months).[16] While 
aggressive therapy with systemic corticosteroids is underway, 
refractory cases are very high, as seen with active inflammation. 
This is the site of immunomodulatory therapy (IMT).[29]
Acute phase of VKH disease needs high-dose corticosteroids 
given as early as possible.[30] Administration of intravenous 
methyl-prednisolone (500–1000 mg/day) for 3 days is 
recommended, which is followed by high-dose oral prednisone 
(1.0–1.2 mg/kg) for 4–6 weeks. Intravenous corticosteroid 
use has not really been proven, but it can help to achieve rapid 
resolution of the inflammation.[31]
Cases of subacute phase VKH disease may benefit from 
the early introduction of non-steroidal immunosuppressive 
agents. To achieve choroiditis-free disease resolution, early 
application of non-steroidal immunosuppressive therapies (e.g., 
mycophenolate mofetil, 1000 mg twice daily, or mycophenolic 
acid, and 720 mg twice daily) was very successful and generally 
well tolerated.[32] The use of these agents is responsible 
for generating pronounced corticosteroid-sparing effects, 
dramatically improve visual outcomes, rather significantly 
reduced the development of chronic persistent inflammation 
and late complications.[33,34]
As mentioned above, refractory patient groups had a better 
functional outcome with early IMT therapy.[29] In the early 
stages of the disease, corticosteroid therapeutic responses 
should be evaluated for the possible value of IMT. Such an 
indicator, including baseline visual acuity <20/200, fundus 
depigmentation, and chronic disease stages.[29] Current evidence 
indicates the benefits of IMT use as a first-line treatment.[16] IMT 
treatment used included many classes of antimetabolic agents 
(methotrexate, azathioprine, and mofetil mycophenolate), 
alkylating agents (cyclophosphamide), biological agents 
(adalimumab and infliximab), and calcineurin inhibitors 
(cyclosporin A).[1]
Topical corticosteroids (dexamethasone eye drops 0.1% 
or prednisolone acetate 1%) can be used in patients with 
iridocyclitis (anterior uveitis). It is combined with cycloplegic 
(example: Tropicamide eye drops 1%) to avoid post-synechiae 
and minimize ciliary spasm.[1]
Immunosuppressive therapy is responsible for downregulating 
several pro-inflammatory cytokines, including IL2, IL3, IL4, 
IL5, IFN-γ, TNF-α, and granulocyte necrosis factor, while 
upregulating the IL-10. It can be used to inhibit the destruction of 
melanocyte mediated by the T1 helper cell.[3]
Complications
Chronic recurrent inflammation is linked to ocular disorders, 
including cataract, glaucoma, and choroid neovascularization. 
Other more uncommon conditions, including cystoid macular 
edema, bulbar phthisis, and optic disk atrophy. It is closely linked 
to the time of referral and onset of illness. Patients who arrive 
faster than 4 weeks of onset (early stage of illness) tend to be less 
likely to develop a complication and recurrence than those who 
arrive later than that.[1]
Prognosis
With rapid and accurate diagnosis, prompt high-dose steroid use 
and immunomodulator at early onset of disease, the prognosis 
of VKH disease is good, although irreversible conditions 
with undesired visual outcome are likely to develop.[11,35,36] 
Good prognosis of visual function is not always accompanied 
favorable outcome of retinal epithelial pigment, which is 
unpredictable.[35] Complications, including glaucoma, cataract, 
and choroidal neovascularization, found to be associated with 
the potentially visual-threatening progression of VKH disease, 
especially in chronic disease phases.
Recent Reports on the Manifestation of VKH Disease
VKH disease did not always come with typical signs and 
symptoms. Unilateral eye involvement is not commonly reported, 
but it can be presented to the hospital, showing specific signs 
on imaging modality.[37] As mentioned above, there are some 
complications of VKH disease, but it is not always come in the 
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later stage of the disease, a report stated the presence of bilateral 
acute angle closure glaucoma as the initial presentation,[38] 
meanwhile, retinal hemorrhage on funduscopy can also be seen 
in the acute stage of the disease,[39] in addition to bilateral disc 
edema.[40] VKH disease also reported to happen simultaneously 
with treatment procedure, including chemoimmunotherapy or 
biologic agent (nivolumab) administration.[41,42]
Conclusion
VKH disease is a diagnosis of exclusion, a comprehensive 
history taking and physical examinations are required for 
prompt treatment of the disease due to its potentially disabling 
adverse effects on the visual function. Early administration 
of corticosteroids is typically used as an agent to improve 
patient outcomes. Further research on this subject is required 
to organize the most effective treatment modality in a widely 
agreed algorithm.
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